LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 12 of 497
Next
>>
>
276 to 300 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Seliciclib	0.04	uM	LJP5	3	J06	72	hr	1097	3831	3769	1.0163	1.0230
BT-20	Ruxolitinib	0.04	uM	LJP5	1	O18	72	hr	1097	3651	3769	0.9686	0.9556
BT-20	Ruxolitinib	0.04	uM	LJP5	2	O18	72	hr	1097	3436	3769	0.9115	0.8752
BT-20	Ruxolitinib	0.04	uM	LJP5	3	O18	72	hr	1097	3975	3769	1.0545	1.0769
BT-20	XL147	0.04	uM	LJP5	1	G12	72	hr	1097	4110	3769	1.0903	1.1274
BT-20	XL147	0.04	uM	LJP5	2	G12	72	hr	1097	4215	3769	1.1182	1.1667
BT-20	XL147	0.04	uM	LJP5	3	G12	72	hr	1097	4581	3769	1.2153	1.3037
BT-20	Saracatinib	0.04	uM	LJP6	1	D12	72	hr	1097	3604	3769	0.9561	0.9381
BT-20	Saracatinib	0.04	uM	LJP6	2	D12	72	hr	1097	3541	3769	0.9394	0.9145
BT-20	Saracatinib	0.04	uM	LJP6	3	D12	72	hr	1097	3354	3769	0.8898	0.8445
BT-20	Selumetinib	0.04	uM	LJP6	1	M12	72	hr	1097	3597	3769	0.9542	0.9354
BT-20	Selumetinib	0.04	uM	LJP6	2	M12	72	hr	1097	3837	3769	1.0179	1.0252
BT-20	Selumetinib	0.04	uM	LJP6	3	M12	72	hr	1097	3694	3769	0.9800	0.9717
BT-20	Sirolimus	0.04	uM	LJP6	1	L18	72	hr	1097	2342	3769	0.6213	0.4658
BT-20	Sirolimus	0.04	uM	LJP6	2	L18	72	hr	1097	2241	3769	0.5945	0.4280
BT-20	Sirolimus	0.04	uM	LJP6	3	L18	72	hr	1097	2519	3769	0.6683	0.5320
BT-20	Sorafenib	0.04	uM	LJP6	1	B12	72	hr	1097	3425	3769	0.9086	0.8711
BT-20	Sorafenib	0.04	uM	LJP6	2	B12	72	hr	1097	3511	3769	0.9314	0.9033
BT-20	Sorafenib	0.04	uM	LJP6	3	B12	72	hr	1097	3299	3769	0.8752	0.8239
BT-20	SU11274	0.04	uM	LJP5	1	J12	72	hr	1097	4265	3769	1.1314	1.1854
BT-20	SU11274	0.04	uM	LJP5	2	J12	72	hr	1097	3959	3769	1.0503	1.0709
BT-20	SU11274	0.04	uM	LJP5	3	J12	72	hr	1097	4270	3769	1.1328	1.1873
BT-20	Fedratinib	0.04	uM	LJP5	1	L06	72	hr	1097	4162	3769	1.1041	1.1469
BT-20	Fedratinib	0.04	uM	LJP5	2	L06	72	hr	1097	4023	3769	1.0672	1.0948
BT-20	Fedratinib	0.04	uM	LJP5	3	L06	72	hr	1097	4135	3769	1.0970	1.1368

|<
<<
Previous
Page 12 of 497
Next
>>
>
276 to 300 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)